<bill session="118" type="s" number="1522" updated="2025-04-21T12:24:17Z">
  <state datetime="2023-05-10">REFERRED</state>
  <status>
    <introduced datetime="2023-05-10"/>
  </status>
  <introduced datetime="2023-05-10"/>
  <titles>
    <title type="display">A bill to require the Secretary of Health and Human Services to conduct a study on the designation of biosimilar biological products as interchangeable.</title>
    <title type="official" as="introduced">A bill to require the Secretary of Health and Human Services to conduct a study on the designation of biosimilar biological products as interchangeable.</title>
  </titles>
  <sponsor bioguide_id="M001198"/>
  <cosponsors/>
  <actions>
    <action datetime="2023-05-10">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2023-05-10" state="REFERRED">
      <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
    </action>
  </actions>
  <committees>
    <committee code="SSHR" name="Senate Health, Education, Labor, and Pensions" subcommittee="" activity="Referred To"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
  </subjects>
  <amendments/>
  <summary date="2023-10-20T15:16:30Z" status="Introduced in Senate">This bill requires the Food and Drug Administration to report on its designation of biosimilars as interchangeable, including the applicable standards, authorities, evidence, and other factors involved in such designations. (Biosimilars that are designated as interchangeable may be substituted for the reference product at a pharmacy without a new prescription, depending on state pharmacy laws.)</summary>
</bill>
